VIDEO: Mirikizumab induces, maintains clinical remission at 1 year in UC patients

SAN DIEGO — Patients with ulcerative colitis who responded to mirikizumab at 12 weeks achieved and maintained clinical remission and improved bowel urgency severity at 1 year in the phase 3 LUCENT-2 study.“The primary endpoint of clinical remission and all key secondary endpoints across clinical, symptomatic, endoscopic and histological measures were met with significance and clinically meaningful effect sizes after 52 weeks of mirikizumab treatment,” Marla C. Dubinsky, MD, professor of pediatrics and medicine at the Icahn School of Medicine at Mount Sinai and co-director ofRead More

Related Articles